{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:12:01Z","timestamp":1792725121041,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,2,10]]},"abstract":"<jats:p>\n            MCARH109 is a first-in-class G protein\u2013coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed\/refractory multiple myeloma. This phase I clinical trial included 17 patients and determined that MCARH109 is safe at a maximum tolerated dose of 150 \u00d7 10\n            <jats:sup>6<\/jats:sup>\n            CAR T cells. In this updated analysis, no new serious adverse events were reported at a median follow-up of 37 months. Overall, 12 (71%) of 17 patients responded, including seven (70%) of 10 patients previously treated with B-cell maturation antigen-targeted therapy. The median duration of response was 8.6 months (95% CI, 5.7 to not reached [NR]) with two patients sustaining a stringent complete response at the time of last follow-up, 32 months and 41 months, respectively. The median overall survival (OS) was NR and the 3-year OS estimate was 59% (95% CI, 40 to 88). Possible GPRC5D loss via immunohistochemistry was observed in 6 (60%) of 10 patients at relapse. High-dimensional spectral cytometry\u2013based immune profiling associated an activated T-cell phenotype at apheresis with a response to MCARH109.\n          <\/jats:p>","DOI":"10.1200\/jco-24-01785","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T20:59:07Z","timestamp":1733345947000},"page":"498-504","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":32,"title":["Phase I Trial of MCARH109, a G Protein\u2013Coupled Receptor Class C Group 5 Member D (GPRC5D)\u2013Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct04555551","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8280-2581","authenticated-orcid":true,"given":"Eric M.","family":"Jurgens","sequence":"first","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-9320","authenticated-orcid":true,"given":"Ross S.","family":"Firestone","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagrutiben","family":"Chaudhari","sequence":"additional","affiliation":[{"name":"Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Hosszu","sequence":"additional","affiliation":[{"name":"Immune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6801-720X","authenticated-orcid":true,"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":true,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Landa","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7807-6775","authenticated-orcid":true,"given":"Devin P.","family":"McAvoy","sequence":"additional","affiliation":[{"name":"Immune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Korde","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":true,"given":"Carlyn R.","family":"Tan","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":true,"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":true,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":true,"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[{"name":"Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-839X","authenticated-orcid":true,"given":"David J.","family":"Chung","sequence":"additional","affiliation":[{"name":"Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-0240","authenticated-orcid":true,"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[{"name":"Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-2702","authenticated-orcid":true,"given":"Ozgur Can","family":"Eren","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":true,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":true,"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[{"name":"Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-5130","authenticated-orcid":true,"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[{"name":"Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7363-3963","authenticated-orcid":true,"given":"Isabelle","family":"Rivi\u00e8re","sequence":"additional","affiliation":[{"name":"Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-7587","authenticated-orcid":true,"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":true,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-9561","authenticated-orcid":true,"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8016"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_8_6_2","volume-title":"CARVYKTI\u00ae Is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients With Relapsed or Refractory Multiple Myeloma Who Have Received At Least One Prior Line of Therapy","author":"Johnson & Johnson","year":"2024","unstructured":"Johnson & Johnson: CARVYKTI\u00ae Is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients With Relapsed or Refractory Multiple Myeloma Who Have Received At Least One Prior Line of Therapy, 2024. https:\/\/www.jnj.com\/media-center\/press-releases\/carvykti-is-the-first-and-only-bcma-targeted-treatment-approved-by-the-u-s-fda-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy#:~:text=HORSHAM%2C%20PA%20(April%205%2C,one%20prior%20line%20of%20therapy"},{"key":"e_1_3_8_7_2","volume-title":"U.S. FDA Approves Bristol Myers Squibb and 2seventy Bio\u2019s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy","author":"Bristol-Myers Squibb","year":"2024","unstructured":"Bristol-Myers Squibb: U.S. FDA Approves Bristol Myers Squibb and 2seventy Bio\u2019s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy, 2024. https:\/\/news.bms.com\/news\/details\/2024\/U.S.-FDA-Approves-Bristol-Myers-Squibb-and-2seventy-bios-Abecma-for-Triple-Class-Exposed-Relapsed-or-Refractory-Multiple-Myeloma-After-Two-Prior-Lines-of-Therapy\/default.aspx#:~:text=(Nasdaq%3A%20TSVT)%20have%20announced,immunomodulatory%20agent%20(IMiD)%2C%20a"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003715"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.047"},{"key":"e_1_3_8_14_2","unstructured":"Allen Institute Publications for Brain Science: Genesearchfor\u201cGPRC5DORPOU4F1OR TNFRSF17 \u201d microarray data Allen human brain atlas. 2022. https:\/\/human.brain-map.org\/microarray\/search\/show?exact_match=false&search_term=GPRC5D%20OR%20POU4F1%20OR%20TNFRSF17&search_type=gene&page_num=0"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11405"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2308544"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00372-6"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181857"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162395"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01824"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00735-4"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00625-9"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022499"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01245-5"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004418"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023557"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0020"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00372-6"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3759"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00763-8"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-24-01785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T22:59:21Z","timestamp":1738796361000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-24-01785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,2,10]]}},"alternative-id":["10.1200\/JCO-24-01785"],"URL":"https:\/\/doi.org\/10.1200\/jco-24-01785","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"2024-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}